CJC-1295 (NO DAC) + Ipamorelin Peptide Blend Molecular Structure & Chemical Properties

The CJC-1295 (NO DAC) + Ipamorelin peptide blend represents one of the most extensively studied growth hormone secretagogue combinations in preclinical research, with investigations spanning over two decades examining their synergistic effects on pituitary growth hormone release. CJC-1295 without Drug Affinity Complex (NO DAC), also known as Modified GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids with four strategic substitutions designed to enhance stability. Ipamorelin, a selective pentapeptide growth hormone secretagogue derived from GHRP-1, was originally developed by Novo Nordisk and represents the first highly selective growth hormone-releasing peptide with minimal effects on other pituitary hormones. When combined in research applications, these peptides demonstrate complementary mechanisms that create a sustained, pulsatile growth hormone release pattern more closely mimicking natural physiological rhythms than either peptide alone.

Chemical Structure

2D molecular structure of CJC-1295 (NO DAC) (Source: PubChem)

2D molecular structure of Ipamorelin peptide (Source: PubChem)

Technical Specifications – CJC-1295 (NO DAC)

Technical Specifications – Ipamorelin

CJC-1295 (NO DAC) contains four amino acid substitutions at positions 2, 8, 15, and 27 from the native GHRH 1-29 sequence, which enhance its resistance to enzymatic degradation while maintaining potent GHRH receptor activation. Ipamorelin’s pentapeptide structure features non-natural amino acids including aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal), contributing to its selective ghrelin receptor binding properties.

CJC-1295 (NO DAC) + Ipamorelin Peptide Blend Mechanism of Action

The CJC-1295 (NO DAC) + Ipamorelin peptide blend exerts synergistic growth hormone-releasing effects through complementary receptor pathways in the anterior pituitary gland. This dual-mechanism approach enables more pronounced and sustained growth hormone secretion than either peptide administered individually, while preserving the natural pulsatile pattern of growth hormone release that maintains physiological feedback mechanisms.

Primary Cellular Pathways

GHRH Receptor Activation – Sustained Pituitary Stimulation

CJC-1295 (NO DAC) functions as a modified growth hormone-releasing hormone analog that binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. Research has demonstrated sustained growth hormone release following administration:

• Enhanced binding affinity to GHRH receptors compared to native GHRH
• Increased resistance to dipeptidyl peptidase-IV enzymatic degradation
• Sustained elevation of plasma growth hormone concentrations for several hours post-administration
• Dose-dependent increases in both growth hormone and IGF-1 levels

Studies have shown that CJC-1295 increases plasma growth hormone levels by 2- to 10-fold for up to 6 days, with IGF-1 levels remaining elevated for 9-11 days following a single dose in human subjects.

Ghrelin Receptor (GHS-R1a) Selective Activation

Ipamorelin acts as a highly selective agonist of the growth hormone secretagogue receptor (GHS-R1a), mimicking the natural hormone ghrelin without affecting other pituitary hormone secretion:

• Selective binding to GHS-R1a receptors without stimulating ACTH, cortisol, or prolactin release
• Rapid onset of growth hormone pulse generation (peak levels within 40-60 minutes)
• No significant effect on appetite stimulation unlike other ghrelin mimetics
• Preserved feedback regulation through endogenous growth hormone-releasing inhibitory mechanisms

Research indicates that ipamorelin releases growth hormone with potency and efficacy similar to GHRP-6 (EC50 approximately 1.3 nmol/L) but with superior selectivity for growth hormone secretion.

Synergistic Amplification Mechanism

When combined, CJC-1295 (NO DAC) and ipamorelin blend peptide create a complementary effect through activation of distinct receptor families:

• CJC-1295 amplifies the frequency and baseline of growth hormone pulses via GHRH receptor stimulation
• Ipamorelin increases the amplitude (peak height) of growth hormone pulses via ghrelin receptor activation
• Combined administration results in 3- to 5-fold greater growth hormone release compared to either peptide alone
• Maintenance of natural pulsatile secretion pattern prevents receptor desensitization

The mechanism involves cooperative signaling through the cyclic AMP (cAMP) and phospholipase C pathways, with GHRH receptor activation increasing intracellular cAMP levels while ghrelin receptor activation potentiates calcium mobilization in somatotroph cells.

IGF-1 Upregulation – Downstream Anabolic Signaling

Both peptides indirectly stimulate insulin-like growth factor-1 (IGF-1) production through sustained growth hormone elevation:

• Growth hormone binds to hepatic GH receptors activating JAK-STAT signaling pathways
• Increased transcription of IGF-1 gene in liver tissue
• Elevated plasma IGF-1 levels mediate anabolic effects in muscle, bone, and adipose tissue
• IGF-1 provides negative feedback regulation preventing excessive growth hormone secretion

Studies report IGF-1 increases of 1.5- to 3-fold for 9-11 days following CJC-1295 administration, with the ipamorelin combination providing more sustained elevation.

CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings

Growth Hormone Secretion Research

Pituitary Function Studies

Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species:

• Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations
• 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose
• Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation
• Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels

Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg.

IGF-1 Elevation Studies

Research has documented significant and prolonged IGF-1 increases following peptide blend administration:

• 1.5- to 3-fold elevation of plasma IGF-1 concentrations lasting 9-11 days after single dose
• Multiple doses resulted in cumulative effects with IGF-1 remaining elevated for up to 28 days
• IGF-1 increases correlated with growth hormone pulse amplitude and frequency
• Liver-mediated IGF-1 production served as primary mediator of downstream anabolic effects

Musculoskeletal Research

Bone Formation and Density

Investigations in rat models have examined the blend’s effects on bone metabolism and skeletal growth:

• Dose-dependent increases in longitudinal bone growth rate from 42 mcm/day (vehicle) to 52 mcm/day at highest dose
• Ipamorelin demonstrated ability to counteract glucocorticoid-induced bone formation suppression in adult rats
• Preserved bone mineral content and improved trabecular architecture in preclinical models
• No adverse effects on femur or tibia length or bone composition parameters

Bone formation markers and osteoblast activity increased in animal models receiving the peptide combination, suggesting potential applications in osteoporosis research.

Muscle Mass and Body Composition

Research in growth hormone-deficient and intact animal models showed effects on lean body mass:

• 15.3% increase in body weight in GH-deficient mice treated with ipamorelin over 9 weeks
• Enhanced protein synthesis and nitrogen retention in skeletal muscle tissue
• Dose-dependent effects on body weight gain and lean mass accretion
• Preserved muscle mass during catabolic conditions in experimental models

Studies using DEXA scanning confirmed increases in lean tissue mass with corresponding reductions in fat mass percentage.

Metabolic Research

Lipolysis and Fat Metabolism

Animal studies have investigated the metabolic effects of enhanced growth hormone secretion:

• Growth hormone-mediated lipolysis through hormone-sensitive lipase activation
• Increased free fatty acid availability for energy utilization
• Preferential reduction of visceral adipose tissue in preclinical models
• Improved insulin sensitivity markers in some experimental conditions

Research suggests growth hormone elevations enhance lipid oxidation while preserving lean tissue during energy restriction.

Gastrointestinal Function Studies

Ipamorelin’s ghrelin-mimetic properties have been studied in gastrointestinal motility research:

• Dose-dependent improvement in gastric emptying in rodent postoperative ileus models
• Enhanced gastrointestinal contractility through cholinergic neuron activation
• Accelerated recovery of bowel function in experimental surgical models
• Effects mediated through ghrelin receptor activation in enteric nervous system

Phase II human trials investigated ipamorelin for postoperative ileus treatment, though results did not reach statistical significance for primary endpoints.

Sleep and Recovery Research

Preclinical studies have examined effects on sleep architecture and recovery processes:

• Growth hormone secretion naturally peaks during slow-wave (deep) sleep phases
• CJC-1295 administration timed with sleep periods enhanced natural nocturnal GH pulses
• Potential improvements in sleep quality through growth hormone pathway modulation
• Enhanced recovery markers in animal models following exercise-induced stress

The peptide combination’s ability to amplify natural nighttime growth hormone pulses makes it relevant for circadian rhythm and sleep research applications.

CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Pharmacokinetics & Metabolism

Absorption & Distribution

The CJC-1295 (NO DAC) + Ipamorelin blend peptide exhibits distinct pharmacokinetic profiles for each component when administered in research settings:

CJC-1295 (NO DAC):

• Subcutaneous administration results in gradual absorption with peak plasma concentrations within 1-4 hours
• Half-life of approximately 30 minutes to 2 hours enables pulsatile growth hormone stimulation
• Distribution throughout systemic circulation with selective binding to pituitary GHRH receptors
• Bioavailability significantly improved compared to native GHRH due to enhanced enzymatic resistance

Ipamorelin:

• Rapid absorption following subcutaneous administration with peak levels at approximately 40 minutes
• Terminal half-life of approximately 2 hours in human pharmacokinetic studies
• Dose-proportional pharmacokinetic parameters across studied dose ranges
• Volume of distribution at steady-state of 0.22 L/kg indicating limited tissue distribution

When administered together, ipamorelin provides rapid-onset growth hormone pulse generation (peak at 0.67 hours) while CJC-1295 maintains elevated baseline growth hormone levels through sustained GHRH receptor activation.

Metabolism & Elimination

Limited characterization of specific metabolic pathways has been published for both peptides:

CJC-1295 (NO DAC):

• Peptidase-mediated degradation represents primary metabolic pathway
• Four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV
• Metabolites and degradation products not fully characterized in published literature
• Clearance from circulation within hours despite sustained pharmacodynamic effects

Ipamorelin:

• Clearance of 0.078 L/h/kg in human pharmacokinetic studies
• Rapid elimination from plasma following distribution phase
• Metabolic pathways likely involve proteolytic cleavage at peptide bonds
• No significant accumulation observed with repeated dosing in animal models

A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-lives (30 minutes to 2 hours), growth hormone secretory effects persist for 6+ hours, suggesting either active metabolites, tissue retention, or persistent receptor signaling cascade activation.

Excretion Pathways

Excretion mechanisms for both peptides remain incompletely characterized:

• Renal filtration likely represents primary elimination route for peptide fragments
• Hepatic metabolism may contribute to peptide degradation and clearance
• No evidence of significant biliary excretion in available studies
• Pharmacokinetic studies in renal or hepatic impairment models are absent from literature

The rapid systemic clearance of both peptides contrasts with prolonged downstream effects on growth hormone and IGF-1, indicating that direct peptide presence is not required for sustained biological activity once pituitary signaling cascades are initiated.

CJC-1295 (NO DAC) + Ipamorelin Blend Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse dosing strategies for both peptides depending on species, research objectives, and desired pharmacodynamic effects:

CJC-1295 (NO DAC) Research Doses:

• Human studies: 30-90 mcg/kg weekly doses in Phase I/II trials
• Rat models: 1 mcmol/kg subcutaneous administration for acute studies
• Cell culture: Picomolar to micromolar concentrations for in vitro growth hormone release assays

Ipamorelin Research Doses:

• Human volunteers: 4.21-140.45 nmol/kg infused over 15 minutes in pharmacokinetic studies
• Rat models: 18-450 mcg/day divided into three daily doses in longitudinal studies
• Swine models: 2.3-3.9 nmol/kg effective doses for growth hormone release

Combination Blend Research Protocols:

• Typical research ratios employ 1:1 to 2:1 (Ipamorelin:CJC-1295) by mass
• Daily to twice-daily administration protocols for sustained effects in animal models
• Weekly to twice-weekly dosing for CJC-1295 component in some research designs

Important: These are experimental doses used in animal studies and early human research and cannot be extrapolated to other species or therapeutic applications due to significant differences in peptide metabolism, receptor density, pharmacokinetics, and species-specific growth hormone regulation. Peptide response varies substantially across species, and no established therapeutic dosing guidelines exist outside research contexts.

Administration Routes in Research

Multiple delivery methods have been investigated for optimal peptide bioavailability:

• Subcutaneous injection – Primary route in human and animal research; reliable systemic absorption
• Intravenous infusion – Used in controlled pharmacokinetic characterization studies
• Intraperitoneal injection – Common in rodent research protocols for systemic delivery
• Intranasal administration – Investigated for GHRH analogs in sleep research applications

Subcutaneous administration represents the most common research route due to ease of delivery, reproducible absorption kinetics, and sustained peptide exposure suitable for growth hormone secretion studies.

Common Model Organisms

The CJC-1295 + Ipamorelin blend has been studied across multiple species and experimental systems:

• Humans – Phase I/II clinical trials in healthy volunteers (ages 21-61); safety and pharmacokinetic characterization
• Rats – Most extensive preclinical database; Sprague-Dawley and Wistar strains; pituitary function, bone formation, metabolic studies
• Mice – Growth hormone-deficient and intact models; body composition and metabolic research
• Swine – Pharmacodynamic studies; growth hormone release characterization
• Primary cell cultures – Rat anterior pituitary cells; in vitro growth hormone secretion assays
• Cell lines – Somatotroph cell cultures for mechanistic receptor studies

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over two decades of preclinical investigation and limited early-phase human studies, the CJC-1295 (NO DAC) + Ipamorelin blend faces substantial evidence gaps that prevent clinical application:

Lack of Human Clinical Data

The most significant limitation is the absence of completed, peer-reviewed Phase III clinical trials:

• No FDA-approved indications for either peptide individually or in combination
• Phase II trials discontinued for CJC-1295 DAC following death of trial participant (though deemed unrelated by attending physician, development ceased as precautionary measure)
• Ipamorelin Phase II trials for postoperative ileus showed no significant efficacy versus placebo and were discontinued
• Long-term human safety profile completely unestablished beyond early-phase studies
• Optimal therapeutic dosing, treatment duration, and patient selection criteria unknown
• No published data on use in pediatric, geriatric, or medically complex populations

Mechanistic Understanding Gaps

Fundamental aspects of the peptide blend’s mechanisms require further elucidation:

• Disconnect between pharmacokinetics and pharmacodynamics – peptides clear rapidly (hours) but effects persist for days; mechanism unexplained
• Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized
• Long-term receptor sensitivity and potential for desensitization inadequately studied
• Individual patient variability in response not well-characterized
• Potential for differential effects based on endogenous growth hormone status unclear

Long-Term Safety Considerations

Critical safety questions remain unanswered regarding chronic peptide administration:

• Cardiovascular safety concerns – FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension
• Immunogenicity risks – FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis
• Cancer risk – theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation; long-term epidemiological data absent
• Metabolic effects – potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies
• Endocrine disruption – effects on other hormonal axes with chronic use not well-studied

Regulatory & Competitive Sport Status

FDA Position

Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication:

• Investigational New Drug status – available only for qualified research applications
• 2024 FDA compounding restrictions – both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review
• Not approved for human use in any formulation or indication
• Warning letters issued to companies marketing peptides for human therapeutic use
• Compounding status uncertain – as of 2024-2025, regulatory position on compounding pharmacy access remains in flux

The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts.

WADA Prohibition

The World Anti-Doping Agency classifies both peptides as prohibited substances for competitive athletes:

• Section S2 classification – Peptide Hormones, Growth Factors, and Related Substances
• Prohibited at all times (both in-competition and out-of-competition)
• No Therapeutic Use Exemptions available – not recognized as legitimate medical treatments
• Performance-enhancing potential acknowledged due to growth hormone secretagogue effects
• Detection methods under development for anti-doping testing programs

WADA’s position reflects that these peptides possess clear performance-enhancing properties and lack approved therapeutic applications that would justify medical use exemptions.

Research Classification: The CJC-1295 (NO DAC) + Ipamorelin blend is available exclusively for laboratory research use by qualified investigators. These peptides are not intended for human consumption, medical treatment, veterinary applications, or any use outside controlled research environments. All research must be conducted under appropriate ethical oversight, institutional review board approval, and regulatory compliance with applicable research standards.

References

1. Raun, K., Hansen, B.S., Johansen, N.L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P.H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed
   
2. Gobburu, J.V., Agersø, H., Jusko, W.J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412-1416. PubMed
   
3. Johansen, P.B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T.T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113. PubMed
   
4. Andersen, N.B., Malmlöf, K., Johansen, P.B., Andreassen, T.T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272. PubMed
   
5. Lall, S., Tung, L.Y., Ohlsson, C., Jansson, J.O., & Dickson, S.L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132-138. PubMed
   
6. Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology, 4, 149-155. PubMed
   
7. Beck, D.E., Sweeney, W.B., McCarter, M.D., & ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. PubMed
   
8. Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D.P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058. PubMed
   
9. Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PubMed
   
10. Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. PubMed
    
11. Alba, M., Fintini, D., Bowers, C.Y., & Salvatori, R. (2006). Effects of long-term treatment with CJC-1295, a long-acting growth hormone-releasing hormone analog, in GH-deficient mice. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. PubMed
    
12. Venkova, K., Mann, W., Nelson, R., & Greenwood-Van Meerveld, B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 329(3), 1110-1116. PubMed
    
13. Adeghate, E., & Ponery, A.S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406. PubMed
    
14. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S.D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-41. Article
    
15. Sinha, D.K., Balasubramanian, A., Tatem, A.J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A.W., & Lipshultz, L.I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149-S159. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. CJC-1295 (NO DAC) + Ipamorelin Blend is intended for laboratory research use only.